Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE) June 11, 2021 -- Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ruxolitinib cream for the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news